# US 2024/0200096 A1 · Methods of redosing gene therapy vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200096 A1
- Document ID: US20240200096A1
- Status: Published application
- Kind: A1
- Application number: 18/479,761
- Filed: 2023-10-02
- Published: 2024-06-20
- Earliest claimed: 2019-05-14
- Assignees: Biomarin Pharmaceutical Inc.
- Applicants: Biomarin Pharmaceutical Inc.
- Inventors: Peter COLOSI; Justin ISHIDA; Silvia RAMIREZ
- Web page: https://patentgrep.com/patent/US20240200096A1

## CPC

- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/0083: {characterised by an aspect of the administration regime}
- C12N 2750/14121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14142: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/85: mammalian
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates, in general, to methods for readministering, or redosing, a subject having undergone a first gene therapy regimen with a second, or subsequent, administration of a gene therapy regimen, wherein the first gene therapy vector and second gene therapy vector comprise different AAV capsids but carry a transgene or polynucleotide useful to treat the same disease or disorder.

## Claims

### Claim at position 1

1-33. (canceled)

### Claim 34

A method of treating a human subject with multiple doses of recombinant adeno-associated virus (rAAV) vectors, the method comprising the following steps:
(a) administering to the human subject a first rAAV vector comprising a first AAV capsid and a transgene encoding a therapeutic molecule, wherein the first AAV capsid comprises a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein, and
(b) assaying for neutralizing antibody titer to a second rAAV vector in a serum sample from the human subject, wherein the second rAAV vector comprises a second AAV capsid and a transgene encoding the same therapeutic molecule or a different therapeutic molecule as the first rAAV vector,
wherein the second AAV capsid comprises a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein, and
wherein the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid has less than or equal to about 80% homology to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid; and
(c) if the neutralizing antibody titer to the second rAAV vector in the serum sample from the human subject is less than the neutralizing antibody titer to the second rAAV vector in human intravenous immunoglobulin (IVIG) in a neutralizing antibody assay, then administering to the human subject the second rAAV vector.

### Claim 35 (depends on 34)

The method of claim 34, wherein:
(a) the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid is between 60% to 80% homologous to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid or
(b) the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid is between 65% to 75% homologous to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid.

### Claim 36

A method of treating a human subject with multiple doses of a recombinant adeno-associated virus (rAAV) vectors, the method comprising the following steps:
(a) administering to the human subject a first rAAV vector comprising a first AAV capsid and a transgene encoding a therapeutic molecule, wherein the first AAV capsid comprises a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein, and
(b) assaying for antibody titer to a second rAAV vector in a serum sample from the human subject, wherein the second rAAV vector comprises a second AAV capsid and a transgene encoding the same therapeutic molecule or a different therapeutic molecule as the first rAAV vector,
wherein the second AAV capsid comprises a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein, and
wherein the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid has less than or equal to about 80% homology to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid; and
(c) if the antibody titer to the second rAAV vector in the serum sample from the human subject is not detectable or the total anti-second rAAV vector IgG titer in the serum sample from the human subject is less than 1:10, 1:20. 1:50, 1:80, 1:100, 1:200, 1:300, 1:400, or 1:500, then administering to the human subject the second rAAV vector.

### Claim 37 (depends on 36)

The method of claim 36, wherein the antibody titer to the second rAAV vector in the serum sample from the human subject is not detectable.

### Claim 38 (depends on 36)

The method of claim 36, wherein the total anti-second rAAV vector IgG titer in the serum sample from the human subject is less than 1:10, 1:20. 1:50, 1:80, 1:100, 1:200, 1:300, 1:400, or 1:500.

### Claim 39 (depends on 36)

The method of claim 36, wherein:
(a) the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid is between 60% to 80% homologous to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid; or
(b) the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid is between 65% to 75% homologous to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid.

### Claim 40

A method of treating a human subject with multiple doses of a recombinant adeno-associated virus (rAAV) vectors, the method comprising the following steps:
(a) administering to the human subject a first rAAV vector comprising a first AAV capsid and a transgene encoding a therapeutic molecule, wherein the first AAV capsid comprises a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein, and
(b) assaying for neutralizing antibody titer to a second rAAV vector in a serum sample from the human subject, wherein the second rAAV vector comprises a second AAV capsid and a transgene encoding the same therapeutic molecule or a different therapeutic molecule as the first rAAV vector,
wherein the second AAV capsid comprises a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein, and
wherein the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid has less than or equal to about 80% homology to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid; and
(c) if the neutralizing antibody titer to the second rAAV vector in the serum sample from the human subject is less than 1:2, 1:5, 1:10, 1:20, 1:50, 1:100, 1:200, 1:300, 1:500, or 1:1000, or the NC50 titer of anti-second rAAV vector neutralizing antibody in the serum sample from the human subject is less than 320, 312, 310, 300, 275, 250, 200, 175, 150, 125, 100, 75, 50, 30, or 25, then administering to the human subject the second rAAV vector.

### Claim 41 (depends on 40)

The method of claim 40, wherein the neutralizing antibody titer to the second rAAV vector neutralizing antibody in the serum sample from the human subject is less than 1:2, 1:5, 1:10, 1:20, 1:50, 1:100, 1:200 or 1:300, 1:500, or 1:1000.

### Claim 42 (depends on 40)

The method of claim 40, wherein the NC50 titer of anti-second rAAV vector neutralizing antibody in the serum sample from the human subject is less than 320, 312, 310, 300, 275, 250, 200, 175, 150, 125, 100, 75, 50, 30, or 25.

### Claim 43 (depends on 40)

The method of claim 40, wherein:
(a) the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid is between 60% to 80% homologous to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid; or
(b) the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid is between 65% to 75% homologous to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid.

### Claim 44

A method of administering a second rAAV vector to a human subject previously administered a first rAAV vector, wherein the first rAAV vector comprises a first AAV capsid and a transgene encoding a therapeutic molecule, wherein the second rAAV vector comprises a second AAV capsid and a transgene encoding the same therapeutic molecule or a different therapeutic molecule as the first rAAV vector, and wherein a serum sample from the human subject has lower neutralizing antibody titer to the second rAAV vector than the neutralizing antibody titer to the second rAAV vector in human intravenous immunoglobulin (IVIG) in a neutralizing antibody assay, the method comprising administering to the human subject the second rAAV vector,
wherein the first AAV capsid comprises a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein,
wherein the second AAV capsid comprises a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein, and
wherein the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid has less than or equal to about 80% homology to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid.

### Claim 45 (depends on 44)

The method of claim 44, wherein:
(a) the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid is between 60% to 80% homologous to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid; or
(b) the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid is between 65% to 75% homologous to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid.

### Claim 46

A method of administering a second rAAV vector to a human subject previously administered a first rAAV vector, wherein the first rAAV vector comprises a first AAV capsid and a transgene encoding a therapeutic molecule, wherein the second rAAV vector comprises a second AAV capsid and a transgene encoding the same therapeutic molecule or a different therapeutic molecule as the first rAAV vector, and wherein a serum sample from the human subject has no detectable antibody titer to the second rAAV vector, or the total anti-second rAAV vector IgG titer in the serum sample from the human subject is less than 1:10, 1:20. 1:50, 1:80, 1:100, 1:200, 1:300, 1:400, or 1:500, the method comprising administering to the human subject the second rAAV vector,
wherein the first AAV capsid comprises a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein,
wherein the second AAV capsid comprises a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein, and
wherein the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid has less than or equal to about 80% homology to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid.

### Claim 47 (depends on 46)

The method of claim 46, wherein the antibody titer to the second rAAV vector in the serum sample from the human subject is not detectable.

### Claim 48 (depends on 46)

The method of claim 46, wherein the total anti-second rAAV vector IgG titer in the serum sample from the human subject is less than 1:10, 1:20. 1:50, 1:80, 1:100, 1:200, 1:300, 1:400, or 1:500.

### Claim 49 (depends on 46)

The method of claim 46, wherein:
(a) the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid is between 60% to 80% homologous to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid; or
(b) the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid is between 65% to 75% homologous to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid.

### Claim 50

A method of administering a second rAAV vector to a human subject previously administered a first rAAV vector, wherein the first rAAV vector comprises a first AAV capsid and a transgene encoding a therapeutic molecule, wherein the second rAAV vector comprises a second AAV capsid and a transgene encoding the same therapeutic molecule or a different therapeutic molecule as the first rAAV vector, and wherein a serum sample from the human subject has less than 1:2, 1:5, 1:10, 1:20, 1:50, 1:100, 1:200 or 1:300, 1:500, or 1:1000 neutralizing titer to the second rAAV vector, or the NC50 titer of anti-second rAAV vector neutralizing antibody in the serum sample from the human subject is less than 320, 312, 310, 300, 275, 250, 200, 175, 150, 125, 100, 75, 50, 30, or 25, the method comprising administering to the human subject the second rAAV vector,
wherein the first AAV capsid comprises a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein,
wherein the second AAV capsid comprises a VP1 capsid protein, a VP2 capsid protein, and a VP3 capsid protein, and
wherein the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid has less than or equal to about 80% homology to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid.

### Claim 51 (depends on 50)

The method of claim 50, wherein the neutralizing antibody titer to the second rAAV vector neutralizing antibody in the serum sample from the human subject is less than 1:2, 1:5, 1:10, 1:20, 1:50, 1:100, 1:200 or 1:300, 1:500, or 1:1000.

### Claim 52 (depends on 50)

The method of claim 50, wherein the NC50 titer of anti-second rAAV vector neutralizing antibody in the serum sample from the human subject is less than 320, 312, 310, 300, 275, 250, 200, 175, 150, 125, 100, 75, 50, 30, or 25.

### Claim 53 (depends on 50)

The method of claim 50, wherein:
(a) the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid is between 60% to 80% homologous to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid; or
(b) the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein of the first AAV capsid is between 65% to 75% homologous to the amino acid sequence of the VP1 capsid protein, the VP2 capsid protein, or the VP3 capsid protein, respectively, of the second AAV capsid.

### Claim 54 (depends on 34)

The method of claim 34, wherein treating the subject with multiple doses of rAAV vectors is for treating a disease or disorder, and wherein the therapeutic molecule encoded by the first rAAV vector and the second rAAV vector is useful for treating the disease or disorder.

### Claim 55 (depends on 36)

The method of claim 36, wherein treating the subject with multiple doses of rAAV vectors is for treating a disease or disorder, and wherein the therapeutic molecule encoded by the first rAAV vector and the second rAAV vector is useful for treating the disease or disorder.

### Claim 56 (depends on 40)

The method of claim 40, wherein treating the subject with multiple doses of rAAV vectors is for treating a disease or disorder, and wherein the therapeutic molecule encoded by the first rAAV vector and the second rAAV vector is useful for treating the disease or disorder.

### Claim 57 (depends on 34)

The method of claim 34, wherein the first AAV capsid and the second AAV capsid are phylogenetically distinct.

### Claim 58 (depends on 36)

The method of claim 36, wherein the first AAV capsid and the second AAV capsid are phylogenetically distinct.

### Claim 59 (depends on 40)

The method of claim 40, wherein the first AAV capsid and the second AAV capsid are phylogenetically distinct.

### Claim 60 (depends on 34)

The method of claim 34, wherein the human subject is immunologically naïve to the first rAAV vector and/or the second rAAV vector.

### Claim 61 (depends on 36)

The method of claim 36, wherein the human subject is immunologically naïve to the first rAAV vector and/or the second rAAV vector.

### Claim 62 (depends on 40)

The method of claim 40, wherein the human subject is immunologically naïve to the first rAAV vector and/or the second rAAV vector.

### Claim 63 (depends on 34)

The method of claim 34, wherein the subject has less than 1:2, 1:5, 1:10, 1:20, 1:50, 1:100, 1:200, 1:300, 1:500, or 1:1000 neutralizing antibody titer to the first rAAV vector in a serum sample from the human subject.

### Claim 64 (depends on 36)

The method of claim 36, wherein the subject has less than 1:2, 1:5, 1:10, 1:20, 1:50, 1:100, 1:200, 1:300, 1:500, or 1:1000 neutralizing antibody titer to the first rAAV vector in a serum sample from the human subject.

### Claim 65 (depends on 40)

The method of claim 40, wherein the subject has less than 1:2, 1:5, 1:10, 1:20, 1:50, 1:100, 1:200, 1:300, 1:500, or 1:1000 neutralizing antibody titer to the first rAAV vector in a serum sample from the human subject.

### Claim 66 (depends on 34)

The method of claim 34, wherein:
(a) the first AAV capsid or the second AAV capsid comprises an AAV capsid protein having the amino acid sequence of: (i) the VP1 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164, (ii) the VP2 capsid protein of any one of SEQ ID NOS:15-89 or 158-164, or (iii) the VP3 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164;
(b) the first AAV capsid or the second AAV capsid comprises an AAV capsid protein having at least 95% identity to the amino acid sequence of: (i) the VP1 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164, (ii) the VP2 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164, or (iii) the VP3 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164;
(c) the first AAV capsid is selected from the group consisting of a capsid of AAV5, Bba.49, Bba.47, and bovine and the second AAV capsid is selected from the group consisting of a capsid of AAV5, Bba.49, Bba.47, and bovine;
(d) the first AAV capsid is selected from the group consisting of a capsid of LK03, AAV5, Bba.49, and bovine, and the second AAV capsid is selected from the group consisting of a capsid of LK03, AAV5, Bba.49, and bovine;
(e) the first AAV capsid is selected from the group consisting of a capsid of rh10, AAV5, Bba.49, and bovine, and the second AAV capsid is selected from the group consisting of a capsid of rh10, AAV5, Bba.49, and bovine; or
(f) the first AAV capsid is AAV5 capsid and the second AAV capsid is Bba.49 capsid.

### Claim 67 (depends on 36)

The method of claim 36, wherein:
(a) the first AAV capsid or the second AAV capsid comprises an AAV capsid protein having the amino acid sequence of: (i) the VP1 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164, (ii) the VP2 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164, or (iii) the VP3 capsid protein of any one of SEQ ID NOS:15-89 or 158-164; or
(b) the first AAV capsid or the second AAV capsid comprises an AAV capsid protein having at least 95% identity to the amino acid sequence of: (i) the VP1 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164, (ii) the VP2 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164, or (iii) the VP3 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164;
(c) the first AAV capsid is selected from the group consisting of a capsid of AAV5, Bba.49, Bb47, and bovine and the second AAV capsid is selected from the group consisting of a capsid of AAV5, Bba.49, Bb47, and bovine;
(d) the first AAV capsid is selected from the group consisting of a capsid of LK03, AAV5, Bba.49, and bovine, and the second AAV capsid is selected from the group consisting of a capsid of LK03, AAV5, Bba.49, and bovine;
(e) the first AAV capsid is selected from the group consisting of a capsid of rh10, AAV5, Bba.49, and bovine, and the second AAV capsid is selected from the group consisting of a capsid of rh10, AAV5, Bba.49, and bovine; or
(f) the first AAV capsid is AAV5 capsid and the second AAV capsid is Bba.49 capsid.

### Claim 68 (depends on 40)

The method of claim 40, wherein:
(a) the first AAV capsid or the second AAV capsid comprises an AAV capsid protein having the amino acid sequence of: (i) the VP1 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164, (ii) the VP2 capsid protein of any one of SEQ ID NOS:15-89 or 158-164, or (iii) the VP3 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164;
(b) the first AAV capsid or the second AAV capsid comprises an AAV capsid protein having at least 95% identity to the amino acid sequence of: (i) the VP1 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164, (ii) the VP2 capsid protein of any one of SEQ ID NOS: 15-89 or 158-164, or (iii) the VP3 capsid protein of any one of SEQ ID NOS:15-89 or 158-164;
(c) the first AAV capsid is selected from the group consisting of a capsid of AAV5, Bba.49, Bb47, and bovine and the second AAV capsid is selected from the group consisting of a capsid of AAV5, Bba.49, Bb47, and bovine;
(d) the first AAV capsid is selected from the group consisting of a capsid of LK03, AAV5, Bba.49, and bovine, and the second AAV capsid is selected from the group consisting of a capsid of LK03, AAV5, Bba.49, and bovine;
(e) the first AAV capsid is selected from the group consisting of a capsid of rh10, AAV5, Bba.49, and bovine, and the second AAV capsid is selected from the group consisting of a capsid of rh10, AAV5, Bba.49, and bovine; or
(f) the first AAV capsid is AAV5 capsid and the second AAV capsid is Bba.49 capsid.

### Claim 69 (depends on 34)

The method of claim 34, wherein the therapeutic molecule is selected from the group consisting of Factor VIII, Factor IX, ATP7B protein, C1 esterase inhibitor (C1-INH), alpha 1 antitrypsin, and galactose-1-phosphate uridyl transferase (GALT), dystrophin, a mini-dystrophin, microdystrophin, phenylalanine hydroxylase (PAH), alpha-galactosidase A, and glucocerebrosidase.

### Claim 70 (depends on 36)

The method of claim 36, wherein the therapeutic molecule is selected from the group consisting of Factor VIII, Factor IX, ATP7B protein, C1 esterase inhibitor (C1-INH), alpha 1 antitrypsin, and galactose-1-phosphate uridyl transferase (GALT), dystrophin, a mini-dystrophin, microdystrophin, phenylalanine hydroxylase (PAH), alpha-galactosidase A, and glucocerebrosidase.

### Claim 71 (depends on 40)

The method of claim 40, wherein the therapeutic molecule is selected from the group consisting of Factor VIII, Factor IX, ATP7B protein, C1 esterase inhibitor (C1-INH), alpha 1 antitrypsin, and galactose-1-phosphate uridyl transferase (GALT), dystrophin, a mini-dystrophin, microdystrophin, phenylalanine hydroxylase (PAH), alpha-galactosidase A, and glucocerebrosidase.
